Hi [[ session.user.profile.firstName ]]

Medical Research

  • Dell's Chief Medical Officer, Dr. Nick van Terhayden on the Future-Ready Display Dell's Chief Medical Officer, Dr. Nick van Terhayden on the Future-Ready Display Dr. Nick van Terhayden - Dell's Chief Medical Officer Recorded: Jul 22 2016 1 min
    Dell's Chief Medical Officer, Dr. Nick van Terhayden on the Future-Ready Display at DW'15

    Before Dr. Nick hovers away on his "Back to the Future" inspired hover board after previewing the Future-Ready innovations on display at the Dell Services booth at Dell World 2015.
  • An app for nursing, designed by nurses An app for nursing, designed by nurses Vincent van Luling, Meander Medisch Centrum & Dell Services Recorded: Jul 22 2016 4 mins
    As part of a wider digitization initiative, Meander Medical Centre wanted to involve nurses in the development of an app that would help them deliver better patient care. The IT team and nursing staff worked with Dell Digital Business Services to design an app that would be used on the Dell Venue 11 Pro tablet, integrating with the hospital’s electronic medical record system.
  • What types of APIs does Scopus offer and how can you benefit? What types of APIs does Scopus offer and how can you benefit? Becky Brown, Market Development Manager Recorded: Jul 21 2016 43 mins
    This webinar will take a look at the Scopus APIs and how you can integrate Scopus content and data into your own websites and applications.
  • What do the upcoming changes to England's pharmacy funding mean? What do the upcoming changes to England's pharmacy funding mean? John Smith, PAGB, Rob Darracott, Pharmacy Voice, Sandra Gidley, English Pharmacy Board Recorded: Jul 21 2016 67 mins
    New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.

    UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?

    Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
  • Multichannel Maturometer 2016 results: Key global trends Multichannel Maturometer 2016 results: Key global trends Ruud Kooi ( VP Business Development, Across Health), Dirk Szynka (MD, Across Health Germany) Recorded: Jul 14 2016 39 mins
    Key topics:

    - Digital maturity of pharma
    - Hot trends in multichannel marketing
    - Evolution of digital budgets
    - Key barriers
  • IOP ebooks - meet the author Wilfred Ngwa IOP ebooks - meet the author Wilfred Ngwa Professor Wilfred Ngwa Recorded: Jul 14 2016 44 mins
    Join us to hear award-winning author Professor Wilfred Ngwa talk through his latest book Emerging Models for Global Health in Radiation Oncology. Highlighting the emerging models for global radiation oncology, this webinar is essential viewing for researchers, students, health professionals and anyone interested in the global oncology community.
  • BREXIT: What's next for pharma? BREXIT: What's next for pharma? Stephen Dorrell, Chair NHS Confederation, Leslie Galloway, EMIG, Prof. Mike Bewick, prev NHS England, Dr Rick Greville, ABPI Recorded: Jul 14 2016 71 mins
    The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.

    Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?

    In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:

    The impact of Brexit on UK Healthcare
    The ramification of Brexit for pharma in the UK
    What does the Brexit scenario mean for global pharma?
  • The value of early asset development and commercialisation The value of early asset development and commercialisation Dominic Tyer Recorded: Jul 13 2016 56 mins
    Linking the clinical benefit of a product to a real-world benefit that markets care about, insurers will pay for and that will improve patients’ lives is critical for pipeline assets to succeed.

    On July 13 Cello Health, in association with PMGroup, will host a free webinar on the value of early asset development and commercialisation.

    It will follow the asset development journey, defining value from both a financial and clinical perspective, and look at the variables with which companies must contend in order to optimize a product’s prospects.
  • Disruptive Technologies and Emerging Trends Drive Life Science Transformation Disruptive Technologies and Emerging Trends Drive Life Science Transformation Transformational Health Team: Nitin Naik, Divyaa Ravishankar, Christi Bird, and Unmesh Lal Recorded: Jul 7 2016 55 mins
    The global pharmaceutical industry is witnessing an unprecedented era. Several new demand spaces such as innovative therapeutics (immuno-oncology), clinical diagnostics (liquid biopsy), and research tools (next-generation sequencing) have emerged, driving companies to sharpen their long-term positions. Fundamental behavioral shifts in these spaces are redefining the market. Companies are adopting a “beyond-the-pill” approach and increasing investments in innovations related to drug discovery, clinical trials, supply-chain solutions, and patient engagement. This briefing reviews recent industry transformations, changes in business models, growth opportunities, and key predictions for the life sciences industry.
  • What's next for patient-centricity? How do we know when we are patient-centric? What's next for patient-centricity? How do we know when we are patient-centric? Jo Fearnhead-Wymbs, Ashfield Healthcare, Anita Osborn, Ashfield Clinical, Andrew Schorr, Patient Power, Paul Robinson, MS Recorded: Jul 5 2016 63 mins
    This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric? How should they measure the impact of their strategy through the lifecycle of a drug and their business as a whole?
  • Developing medical education that advances patient outcomes Developing medical education that advances patient outcomes Dominic Tyer Recorded: Jun 30 2016 56 mins
    As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in clinical practice and advancing patient outcomes.

    Medical education has the potential to affect a significant number of healthcare professionals’ (HCPs) clinical practice and so improve patients’ outcomes.

    Nonetheless, achieving these goals requires medical education to move beyond didactic message delivery - that only improves HCPs’ awareness - to using many multi-channel educational interventions to drive real behaviour change.

    In this webinar, Lucid will discuss why, as an industry, we should all be moving beyond our internal goals to think about how we can improve patient outcomes with all our programmes and share a process for creating measurable improvements.
  • Ray Optics Simulations with COMSOL Multiphysics Ray Optics Simulations with COMSOL Multiphysics Dr Edmund Dickinson Recorded: Jun 29 2016 61 mins
    The Ray Optics Module simulates electromagnetic wave propagation when reflection and refraction are the most important effects. This is the case when the wavelength is short compared with device size. Industrial applications include common optical components such as reflectors, monochromators, lenses and polarizers.
    This webinar will introduce the tools in COMSOL Multiphysics® for analysis of geometrical optics, including ray intensity and polarization calculations; ray propagation in graded media; and multiphysics coupling to other physics such as heat transfer.
    The webinar will include a live demo and conclude with a Q&A session.
  • Transforming Medical Affairs with fact-based solutions and improved compliance Transforming Medical Affairs with fact-based solutions and improved compliance Blake Morrison; Harleen Parmar; Seth Whitelaw; Paul Tunnah Recorded: Jun 28 2016 67 mins
    In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success.

    This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic programs.

    With a wealth of information available, it can be difficult to sort through data and understand what is important to incorporate into research and strategy. In this session you’ll hear needs and use cases for having a robust data strategy when it comes to Medical Affairs success. The panelists will share best practices for making fact-based decisions that meet compliance restrictions, using powerful market insights gained from multiple data sources, to optimize strategic planning and ultimately drive product success.
  • Social medical: The social media buzz around ASCO 2016 Social medical: The social media buzz around ASCO 2016 Paul Tunnah, Dr Mike Thompson, Dr Richard Simcock, Silja Chouquet, Andrew Schorr Recorded: Jun 27 2016 64 mins
    The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year.

    As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year.

    This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it will potentially continue to evolve into 2017.
  • Skin Cancer and Immunohistochemistry Skin Cancer and Immunohistochemistry Jeff Gordon, Director OEM Sales - Cell Marque Corporation, Rocklin CA Recorded: Jun 22 2016 63 mins
    Skin cancer is by far the most prevalent cancer. Each year, approximately 3.4 million people in the US alone are diagnosed with some form of skin cancer. Skin cancer can be highly treatable if it is detected and classified early, and this detection and classification is often aided by immunohistochemistry. This presentation covers many of the basic science, facts, and statistics of skin cancer, as well as the utility of immunohistochemical testing with markers such as S-100, SOX-10, Ber-Ep4, and HHV-8 in the accurate diagnosis and survival rates of skin cancer. Continuing education credits for attending this webinar will be offered through the National Society of Histotechnology
  • Scopus: Using the right metrics Scopus: Using the right metrics Norman Azoulay, Product Manager, Scopus Recorded: Jun 16 2016 43 mins
    This webinar will focus on the metrics that Scopus offers at the article, author, and journal level
  • Food fortification part two: the economic benefits of nutrient-energy density Food fortification part two: the economic benefits of nutrient-energy density Prof. Adam Drewenowski, Prof. Manfred Eggersdorfer, Jacob Bauly Recorded: Jun 16 2016 59 mins
    Continued innovation in food fortification is allowing food manufacturers the opportunity to create products that are not only nutritious, but also convenient, cost-effective and appealing to consumers. Information about nutrient density can help identify foods that have a low cost to nutrient ratio and as part of affordable diets that meet nutritional needs.
    Join us for the second of two webinars on food fortification. This session will focus on the economic benefits of food fortification and nutrient-energy density. The webinar will be presented by Prof. Adam Drewnowski, Professor of Epidemiology, University of Washington, and he will be joined by DSM’s Prof. Manfred Eggersdorfer and Jacob Bauly.

    They will present the economic benefits that food fortification and nutrient-energy density can provide, share examples of how food fortification can achieve these benefits, and explain how these can be applied to product development.

    This presentation is developed for scientific information purposes only and is not intended for marketing and/or sales claims purposes.
  • Pharmaceutical  Manufacturing in the 21st Century-From Batch to Continuous Manuf Pharmaceutical Manufacturing in the 21st Century-From Batch to Continuous Manuf Dr Sau (Larry) Lee & Dirk Leister Recorded: Jun 15 2016 76 mins
    The FDA’s Office of Pharmaceutical Quality (OPQ) is working to encourage the development and adoption of emerging technologies in the pharmaceutical industry that have potential to enhance drug product quality. To achieve this goal, OPQ established the emerging technology team (ETT) program and focuses on advancing regulatory science for emerging technologies. OPQ has identified Continuous Manufacturing as one such emerging technology which has the potential to increase the efficiency, flexibility, agility, and robustness of pharmaceutical manufacturing. The ETT provides industry early engagement opportunities with FDA to receive feedback on potential technical and regulatory issues and FDA’s recommendations for regulatory submission content related to continuous manufacturing and other emerging technologies. In addition, OPQ has started a regulatory science and research program on continuous manufacturing to address remaining gaps in our knowledge and experience. Our research program is currently focused on the following areas in (1) integrated process modeling, (2) understanding of the impact of material properties, and (3) implementation of advanced process control strategies and real time release testing. The results and knowledge developed in this program can be utilized to support the implementation of continuous manufacturing and to ensure that FDA regulatory policies reflect state-of-the-art manufacturing science.
  • Growing Cell Line Potential: From Lab To Licence S2 Growing Cell Line Potential: From Lab To Licence S2 Dr. Lily Chan, Cambridge Enterprise Recorded: Jun 9 2016 26 mins
    A scientific overview of the portfolio of cell lines University of Cambridge has deposited at ECACC with a focus on the KARPAS 299 and KARPAS 422 cell lines; the HeLa Mitotrap cell lines; and CHO cell lines. We will also provide an overview of the process of partnering with ECACC and Sigma-Aldrich for the storage and distribution of cell lines for research purposes. Topics include: The scientific applications of the cell lines; The types of companies and institutions we license to; Advantages of partnering with culture experts and specialised distributors; Our experience of working with ECACC and Sigma-Aldrich.
  • Growing Cell Line Potential: From Lab To Licence S1 Growing Cell Line Potential: From Lab To Licence S1 Dr. Lily Chan, Cambridge Enterprise Recorded: Jun 9 2016 24 mins
    A scientific overview of the portfolio of cell lines University of Cambridge has deposited at ECACC with a focus on the KARPAS 299 and KARPAS 422 cell lines; the HeLa Mitotrap cell lines; and CHO cell lines. We will also provide an overview of the process of partnering with ECACC and Sigma-Aldrich for the storage and distribution of cell lines for research purposes. Topics include: The scientific applications of the cell lines; The types of companies and institutions we license to; Advantages of partnering with culture experts and specialised distributors; Our experience of working with ECACC and Sigma-Aldrich.
  • Leading the New American Hospital: Strategies for Success Leading the New American Hospital: Strategies for Success Tanvir Jaikishen and Patrick Riley Recorded: Jun 7 2016 34 mins
    Why You Must Attend:
    • For hospitals to succeed, it is imperative to create a strategy that allows optimal alignment of care provision between providers. There is no “one-size-fits-all approach” to remain competitive.
    •This briefing assesses different strategies adopted by hospitals, which range from smart collaborations with different ambulatory care providers to efficiently manage care transition, adoption of data integration solutions to better create standards of care protocols, and launch of in-house insurance plans to increase patient volumes.
    • An understanding of these strategies is critical for hospitals to create bespoke integrated care delivery solutions that can be used to address local requirements.
    • This briefing also highlights the financial impact of adopting such integrated models of care delivery.
  • The dangers of using a laboratory developed test as a companion diagnostic The dangers of using a laboratory developed test as a companion diagnostic Keith Miller, FIBMS, Director, UKNEQAS-ICC&ISH Recorded: Jun 1 2016 51 mins
    Companion diagnostic tests are most commonly used to determine patient eligibility for specific therapies and are designed to ensure the therapy is administered safely to patients who are most likely to benefit. Thus, companion diagnostic tests are crucial in facilitating personalized healthcare for the individual patient. Join us as Keith Miller, FIBMS, Director of the United Kingdom National External Quality Assessment Scheme for Immunohistochemistry and In Situ Hybridisation (UKNEQAS-ICC&ISH), addresses the inherent risks in using laboratory developed tests as companion diagnostics, and the role of external quality assessment schemes (EQA) in helping laboratories monitor and maintain quality testing.
  • Impact measurement; from counting numbers to actionable insights Impact measurement; from counting numbers to actionable insights Jan Keuppens (VP Integrated Execution, Across Health) and Christophe Brock (Senior Consultant, Across Health) Recorded: May 31 2016 52 mins
    The key topics that will be discussed during this interactive webinar include:

    •The AH impact measurement approach; Exposure, engagement, conversion and effectiveness
    •Defining KPIs relevant to your brand strategy & objectives
    •Best case – Worst case
    •Creating a dashboard
    •Q&A
  • A Practical guide to Peer Review for Early Career Researchers A Practical guide to Peer Review for Early Career Researchers Jason Roberts, Origin Editorial; Emma Boxer, Wiley; Hakim Meskine, Wiley; Verity Warne, Wiley. Recorded: May 26 2016 61 mins
    Find out how more about the specifics of the peer review process, how to perform a peer review, and the most important dos and don’ts.

    Wiley Author Services presents a practical guide to Peer Review. If you’re new to the process or need to know the best way to give feedback, this webinar is for you! Our experienced team will:
    - Outline the processes involved, including the emails and alerts you will receive.
    - Show you how to construct your Peer Review report
    - Run through the Do’s and Don’ts of giving constructive feedback
  • Finally -- Evidence-Based Best Practices For Using UV Disinfection Equipment Finally -- Evidence-Based Best Practices For Using UV Disinfection Equipment Dr. William Jarvis MD, Dr. Thomas Kelley MD Recorded: May 25 2016 62 mins
    You wouldn’t operate a ventilator or administer an IV without knowing there are scientific studies that back up your procedures. You learned best practices supported by scientific research.

    We have the science and consensus to support UV disinfection best practices. Best practices that have resulted in infection rate reductions in real hospital environments.

    Your discussion will be led by esteemed experts Dr. William Jarvis and Dr. Thomas Kelley.

    William Jarvis, MD is a world leader in infection prevention. Among many other accomplishments he worked at the Centers for Disease Control and Prevention for 23 years, and has published over 450 peer reviewed papers. Recently it was said of Dr. Jarvis, “His decades of service and uncompromised commitment to [infection prevention] has lead to changes in how infection control is administered and has saved many lives.”

    Dr. Jarvis will discuss:
    -Most recent CDC and SHEA guidelines, and the metrics involved
    -A review of the science available on UV technologies in the market
    -What to look for when evaluating a UV technology

    Thomas Kelley, MD is Chief of Quality and Clinical Transformation at Orlando Health. He is a practicing primary care physician in Florida and has been a champion of quality improvement his entire career. He developed the first quality improvement council for the residency program when he was a faculty physician training residents at Atlanta Medical Center, and has continued to give his time and expertise to the causes of patient safety and quality care ever since. Colleagues say, “Dr. Kelley is a true champion for quality.”

    Dr. Kelley will discuss:
    -An integrated disinfection program with pulsed xenon enlightening best practices
    -Review of the results from a system-wide deployment of pulsed xenon light technology
    -How they achieved a $3.8M cost avoidance from HAI rate reduction in 12 months